# A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)

> **NCT01544114** · PHASE4 · COMPLETED · sponsor: **Amgen** · enrollment: 46 (actual)

## Conditions studied

- Juvenile Idiopathic Arthritis (JIA)

## Interventions

- **DRUG:** VIMOVO 250/20
- **DRUG:** VIMOVO 375/20
- **DRUG:** VIMOVO 500/20

## Key facts

- **NCT ID:** NCT01544114
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2015-02
- **Final completion:** 2015-02
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01544114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01544114, "A Safety Study of VIMOVO in Adolescents With Juvenile Idiopathic Arthritis (JIA)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01544114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*